Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96T52

UPID:
IMP2L_HUMAN

ALTERNATIVE NAMES:
IMP2-like protein

ALTERNATIVE UPACC:
Q96T52; Q75MF1; Q75MN9; Q75MP0; Q75MS5; Q75MS8; Q96HJ2

BACKGROUND:
The protein Mitochondrial inner membrane protease subunit 2, alternatively known as IMP2-like protein, is pivotal for mitochondrial protein targeting. It ensures the precise removal of transit peptides, enabling proteins' passage from the mitochondrial matrix to the inter-membrane space, with DIABLO processing being a notable function.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Mitochondrial inner membrane protease subunit 2 could open doors to potential therapeutic strategies, especially considering its link to Gilles de la Tourette syndrome, marked by a spectrum of behavioral abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.